Close Menu

PerkinElmer, Helix GenePrism:Actionable Insights

Apr 02, 2019

PerkinElmer and Helix have launched GenePrism:Actionable Insights, a genetic screening test that they said is the "most comprehensive clinical grade DNA sequencing and interpretation" test currently on the market. The test allows users to learn about their risk for underlying diseases. A user's DNA will be sequenced by Helix and the results will be interpreted by board-certified geneticists at PerkinElmer Genomics using ordered data interpretation network, that firm's proprietary high-throughput software platform. In comparison to other commercial firms that look at a limited number of letters in a gene sequence, GenePrism:Actionable Insights assesses each of 59 genes in its entirety, including BRCA1/2, the partners said. They also noted that PerkinElmer Genomics maintains one of the largest databases of known genetic variations from different ancestries globally providing customers with a more in-depth assessment. 

More Like This

Jan 14, 2020

Biocept Target Selector for CSF

Biocept's Target Selector liquid biopsy assays are now available to physicians to evaluate patients' cerebrospinal fluid for the presence of circulating tumor cells and biomarkers for patients with breast or lung cancer suspected of brain or central nervous system metastases. The presences of such cells may indicate brain metastases. Biocept said that up to 30 percent of patients with breast cancer and up to 36 percent of patients with lung cancer will develop brain metastases.  

Jan 13, 2020

Bio-Rad Laboratories: SEQuoia

Bio-Rad Laboratories announced the launch of the SEQuoia Complete Stranded RNA Library Prep Kit for RNA-Seq library preparation. The kit uses SEQzyme, an enzyme that couples cDNA synthesis with adapter addition in a continuous synthesis reaction. It is compatible with a broad range of sample inputs and allows capture of the complete transcriptome, including short and long RNAs, in a single library prep. The kit generates cDNA libraries suitable for strand-specific next-generation sequencing on Illumina sequencers in less than four hours. It also includes access to the integrated SeqSense analysis solution to process and quality control sequencing data for all RNA biotypes in the library within a single analysis pipeline.

Jan 13, 2020

OncoCyte DetermaRx

OncoCyte has launched the DetermaRx, test for identifying early-stage lung cancer patients who may benefit from adjuvant chemotherapy after surgical resection. The test was formerly known as the Razor treatment stratification test and was being developed by Razor Genomics, which OncoCyte acquired in September. Regulators in Canada have approved the test for marketing in that country, the Irvine, California-based firm said. In the US, Florida Precision Oncology and the Leonard Cancer Institute at Mission Hospital in Mission Viejo, California have signed up as early access users of the test, OncoCyte said. It said that in a clinical study, high-risk patients identified by the test post-surgery and treated with adjuvant chemotherapy had a "significant" increase in survival rates. 

Jan 13, 2020

Sphingotec: IB10 Sphingotest PenKit

SphingoTec has launched its IB10 sphingotest penKit. The CE-IVD-marked point-of-care test for proenkephalin allows for the real-time assessment of kidney function with a blood test. The test will be made available in Europe and other geographies that accept CE-IVD certification at the end of this month to the critical care community for further clinical evaluation. It will be available for use with Sphingotec's rapid POC platform, the Nexus IB10 that uses whole-blood samples without preprocessing, requires less than three minutes of hand-on time, and delivers test results in 20 minutes. 

Jan 09, 2020

Personalis NeXT Dx Test

Personalis has launchedthe NeXT Dx Test, a next-generation sequencing panel designed to help oncologists identify potential therapies and clinical trial options for cancer patients. The assay analyzes approximately 20,000 genes in both the tumor exome and transcriptome, and includes advanced analytics to provide a diagnostic report on genetic alterations in medically important cancer genes, as well as emerging immunotherapy-related biomarkers such as microsatellite instability status and tumor mutational burden.

Jan 08, 2020

Viracor Eurofins 'Viracor TRAC'

Viracor Eurofins has begun offering its Viracor TRAC donor-derived, cell-free DNA assay for diagnosing kidney transplant rejection. The noninvasive liquid biopsy test has similar characteristics to other donor-derived cfDNA assays on the market, Viracor Eurofins said. Two ongoing prospective and one retrospective clinical trials are underway to further develop clinical data to support use of the test. The current gold standard for diagnosing kidney transplant rejection and surveillance is organ biopsy, which is both expensive and can lead to multiple complications for the patient, the firm noted. 

Jan 07, 2020

PreventionGenetics Rapid PGxome WES Test

PreventionGenetics has added the Rapid PGxome whole-exome sequencing test to its clinical testing menu. It is ideal for situations where a rapid genetic diagnosis is essential, including patients with neonatal, infantile,  or early childhood onset severe disorders, the company noted. Rapid PGxome starts at $2,290 per test and must be ordered by a qualified healthcare provider. It has a turnaround time of 14 days and, in cases with a clear positive result, a preliminary report may be issued in as few as six days.

Jan 06, 2020

Sysmex Ipsogen JAK2 DX

Sysmex has launched the ipsogen JAK2 DX reagent after the product received health insurance coverage in Japan on Jan. 1. The Kobe, Japan-based firm said that it received marketing approval for the gene testing kit that measures the JAK2V617F mutation quantitatively in December 2018. The test is used to diagnose certain hematopoietic tumors, specifically polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Sysmex inked a distribution deal with Ipsogen (now part of Qiagen) in 2011 covering Japan that allows Sysmex to distribute some Ipsogen blood cancer products in that country.

Dec 16, 2019

SpeeDx: ResistancePlus MG FleXible

SpeeDx has launched the ResistancePlus MG FleXible for the GeneXpert System in Europe. The test detects Mycoplasma genitalium and markers associated with azithromycin resistance. It is now available in France and the UK, to be followed by the rest of the EU, Australia, and New Zealand. Cepheid is the exclusive distribution partner of the test through its FleXible Cartridge program for the GeneXpert System.

Dec 16, 2019

Anixa Biosciences Cchek Prostate Cancer Confirmation Test

Anixa Biosciences launched its Cchek Prostate Cancer Confirmation test, which leverages the firm's AI- and flow cytometry-based liquid biopsy platform. The Cchek PCC test will be offered as a CLIA-validated test through Anixa's partner laboratory, ResearchDx, which validated it. The test, which uses a blood draw, is meant to confirm the need for prostate biopsy by measuring a patient's immunological response to malignancy by analyzing immune system cells in peripheral blood.

Dec 09, 2019

ELITechGroup Macroduct Advanced Sweat Collection System

In vitro diagnostic equipment and reagent company ELITechGroup has launched its Macroduct Advanced Sweat Collection System in Canada. The system further standardizes pilocarpine iontophoresis and sweat collection and has a touch screen interface with step-by-step graphical instructions, the company said. The new system also has revised electrode shapes to make it easier to work with neonates and toddlers. 

The company's other products include the Webster Sweat Inducer and the Macroduct Sweat Collection System. 

Dec 04, 2019

Quadrant Biosciences Clarifi ASD

Quadrant Biosciences has launched Clarifi ASD, an epigenetic test designed to aid in the diagnosis of autism spectrum disorder in children 18 months through six year of age. Quadrant said the test is based on regulatory RNAs and microbes in the saliva, and is the result of seven years of research in collaboration with SUNY Upstate Medical University and Penn State College of Medicine. Clarifi is a prescription-only, laboratory-developed test that is intended to be used as an additional tool to standard practices and only for children with a clinical suspicion of ASD, the company said. It is available in all states except New York.

Dec 02, 2019

Versiti P-Selectin Expression Assay for Heparin-Induced Thrombocytopenia

Versiti has launched its P-Selectin Expression Assay (PEA) for testing patients suspected of having heparin-induced thrombocytopenia (HIT).

HIT is an immune-mediated drug interaction that is difficult to diagnose. When left untreated, it can progress to thrombosis, the development or growth of blood clots within a blood vessel.

Compared to a current test for detecting HIT, the serotonin release assay, the PEA can detect more patients with HIT antibodies, Versiti said. Its PEA test has a turnaround time of less than 24 hours.

Nov 27, 2019

Devyser HBOC Kit for Hereditary Breast, Ovarian Cancer Testing

Swedish genetic test developer Devyser has launched the HBOC kit for hereditary breast and ovarian cancer testing. The kit is based on Devyser's proprietary next-generation sequencing library prep technology, and provides targeted sequencing of 12 genes in which mutations are associated with an increased risk of developing breast and ovarian cancer. The company said that the workflow takes less than 45 minutes. The HBOC kit is part of Devyser's NGS Oncology suite, complementing the company's BRCA kit that enables simultaneous screening of mutations in the BRCA1 and BRCA2 genes. The new kit is available in the EU and through Devyser distributors in several countries in the Middle East, Southeast Asia, China, South America, and Africa. Customers in countries in which Devyser does not have distributors currently (e.g. the US and Canada) can self-import the assay, a company spokesperson said.

Nov 25, 2019

Siemens Healthineers Enhanced Liver Fibrosis Testing Service

Siemens Healthineers has launched its Enhanced Liver Fibrosis testing service in the US. The service is provided by the Siemens Healthcare Laboratory unit that can test samples submitted from all states in the US, Washington, DC, and Puerto Rico, excluding New York state. The test uses a small blood sample from a patient and provides a unitless numeric score that combines the quantitative measurements in a serum sample of three markers of liver fibrosis — hyaluronic acid, amino-terminal propeptide of type III procollagen, and tissue inhibitor of metalloproteinase. The score can help identify chronic liver disease patients, including those with non-alcoholic fatty liver disease, and stratify individuals at risk of progressing to liver-related events. Siemens noted that the test is not approved by the US Food and Drug Administration.